{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:24:35Z","timestamp":1782307475938,"version":"3.54.5"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jvacx.2024.100556","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T01:04:58Z","timestamp":1727399098000},"page":"100556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A literature review and evidence-based evaluation of the Dutch national immunisation schedule yield possibilities for improvements"],"prefix":"10.1016","volume":"20","author":[{"given":"A.J.M.","family":"Pluijmaekers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7474-1149","authenticated-orcid":false,"given":"A.","family":"Steens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Houweling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.Y.","family":"Rots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.S.M.","family":"Benschop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.","family":"van Binnendijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bodewes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.M.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Buisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Duizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.C.M.","family":"van Els","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Hament","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"den Hartog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kaaijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kerkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.R.M.","family":"van der Klis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Korthals Altes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.A.T.","family":"van der Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"van Meijeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Middeldorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.D.","family":"Rijnbende-Geraerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.M.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.K.","family":"Veldhuijzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Vlaanderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.G.","family":"Voordouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.R.A.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Woudenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"van Vliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.E.","family":"de Melker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2024.100556_b0005","unstructured":"Houweling H, de Melker HE. Optimalisation of the schedule of the National Immunisation Programme. Background information for the advice of the Health Council of The Netherlands on the vaccination schedule of the National Immunisation Programme 2021. Available from: https:\/\/www.rivm.nl\/publicaties\/optimalisation-of-schedule-of-national-immunisation-programme-background-information."},{"key":"10.1016\/j.jvacx.2024.100556_b0010","unstructured":"National Institute for Public Health and the Environment (RIVM). Vaccination coverage and annual report of the National Immunisation Programme in the Netherlands, 2022; 2023."},{"key":"10.1016\/j.jvacx.2024.100556_b0015","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-2458-11-102","article-title":"Religious subgroups influencing vaccination coverage in the Dutch Bible belt: an ecological study","volume":"11","author":"Ruijs","year":"2011","journal-title":"BMC Public Health"},{"issue":"17","key":"10.1016\/j.jvacx.2024.100556_b0020","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1016\/j.vaccine.2010.02.021","article-title":"National Immunisation Programme Review Committee of the Health Council of the N. Criteria for inclusion of vaccinations in public programmes","volume":"28","author":"Houweling","year":"2010","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100556_b0025","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00103-009-0954-x","article-title":"Needs and obstacles of uniform immunisation schedules in the European Union","volume":"52","author":"Wiese-Posselt","year":"2009","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"10.1016\/j.jvacx.2024.100556_b0030","unstructured":"World Health Organization. Principles and considerations for adding a vaccine to a national immunization programme. From decision to implementation and monitoring; 2014."},{"key":"10.1016\/j.jvacx.2024.100556_b0035","unstructured":"Health Council of the Netherlands. Evaluation schedule national immunisation programme (in Dutch) 2022. Available from: https:\/\/www.gezondheidsraad.nl\/onderwerpen\/vaccinaties\/alle-adviezen-over-vaccinaties\/evaluatie-schema-rijksvaccinatieprogramma."},{"issue":"31","key":"10.1016\/j.jvacx.2024.100556_b0040","first-page":"417","article-title":"Diphtheria vaccine: WHO position paper - August 2017","volume":"92","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.jvacx.2024.100556_b0045","unstructured":"National Institute for Public Health and the Environment (RIVM). The national immunisation programme in the Netherlands. Surveillance and developments in 2022\u20132023; 2023. Available from: https:\/\/www.rivm.nl\/publicaties\/rvp-2023."},{"issue":"2","key":"10.1016\/j.jvacx.2024.100556_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148605","article-title":"Long-term protection against diphtheria in the Netherlands after 50 years of vaccination: results from a seroepidemiological study","volume":"11","author":"Swart","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jvacx.2024.100556_b0055","unstructured":"Plotkin S, Orenstein WA, Offit PA. Vaccines. 7 ed2018."},{"issue":"9","key":"10.1016\/j.jvacx.2024.100556_b0060","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/cid\/ciw066","article-title":"Durability of vaccine-induced immunity against tetanus and diphtheria toxins: a cross-sectional analysis","volume":"62","author":"Hammarlund","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"42","key":"10.1016\/j.jvacx.2024.100556_b0065","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1016\/j.vaccine.2018.08.051","article-title":"Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults","volume":"36","author":"Brandon","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100556_b0070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jpids\/pix113","article-title":"Randomized controlled trial of the safety and immunogenicity of revaccination with tetanus-diphtheria-acellular pertussis vaccine (Tdap) in adults 10 years after a previous dose","volume":"8","author":"Halperin","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.jvacx.2024.100556_b0075","unstructured":"National Institute for Public Health and the Environment (RIVM). Current figures on whooping cough in the Netherlands; 2024. Available from: https:\/\/www.rivm.nl\/en\/whooping-cough\/current-figures-on-whooping-cough-in-netherlands."},{"issue":"5","key":"10.1016\/j.jvacx.2024.100556_b0080","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.vaccine.2022.12.061","article-title":"Reactogenicity and safety of second trimester maternal tetanus, diphtheria and acellular pertussis vaccination in the Netherlands","volume":"41","author":"Immink","year":"2023","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100556_b0085","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1473-3099(18)30717-5","article-title":"Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial","volume":"19","author":"Barug","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100556_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-002985","article-title":"Maternal and neonatal antibody levels on pertussis vaccination in pregnant women on immune-modulating therapy for rheumatic disease","volume":"9","author":"Ghalandari","year":"2023","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100556_b0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.24608","article-title":"Maternal pertussis immunization and immunoglobulin G levels in early- to late-term and preterm infants","volume":"7","author":"Immink","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100556_b0100","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1128\/CVI.00695-14","article-title":"Identification of pertussis-specific effector memory T cells in preschool children","volume":"22","author":"de Rond","year":"2015","journal-title":"Clin Vaccine Immunol"},{"issue":"34","key":"10.1016\/j.jvacx.2024.100556_b0105","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1016\/j.vaccine.2011.05.094","article-title":"Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age","volume":"29","author":"Hendrikx","year":"2011","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100556_b0110","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1128\/CVI.00277-12","article-title":"T-cell responses before and after the fifth consecutive acellular pertussis vaccination in 4-year-old Dutch children","volume":"19","author":"Schure","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"8","key":"10.1016\/j.jvacx.2024.100556_b0115","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.vaccine.2006.10.048","article-title":"Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life","volume":"25","author":"Guiso","year":"2007","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.jvacx.2024.100556_b0120","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1600-0463.2009.02554.x","article-title":"Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program","volume":"117","author":"Hallander","year":"2009","journal-title":"APMIS"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100556_b0125","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1017\/S0950268813000071","article-title":"Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin","volume":"142","author":"Mooi","year":"2014","journal-title":"Epidemiol Infect"},{"issue":"Suppl 5","key":"10.1016\/j.jvacx.2024.100556_b0130","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1093\/cid\/civ512","article-title":"MenAfriVac as an Antitetanus Vaccine","volume":"61","author":"Borrow","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"25","key":"10.1016\/j.jvacx.2024.100556_b0135","first-page":"3573","article-title":"Tetanus vaccines: WHO position paper, February 2017 - Recommendations","volume":"36","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100556_b0140","unstructured":"Borrow R, Balmer P, Roper MH. The immunological basis for immunization series In: Module 3: tetanus update 2006. WHO; 2006."},{"key":"10.1016\/j.jvacx.2024.100556_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00681","article-title":"Robust humoral and cellular immune responses to pertussis in adults after a first acellular booster vaccination","volume":"9","author":"van der Lee","year":"2018","journal-title":"Front Immunol"},{"issue":"1\u20132","key":"10.1016\/j.jvacx.2024.100556_b0150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jim.2013.01.001","article-title":"CD4 T-helper cell cytokine phenotypes and antibody response following tetanus toxoid booster immunization","volume":"390","author":"Livingston","year":"2013","journal-title":"J Immunol Methods"},{"issue":"49","key":"10.1016\/j.jvacx.2024.100556_b0155","doi-asserted-by":"crossref","first-page":"7803","DOI":"10.1016\/j.vaccine.2010.09.036","article-title":"High tetanus antitoxin antibody concentrations in the Netherlands: a seroepidemiological study","volume":"28","author":"Steens","year":"2010","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.jvacx.2024.100556_b0160","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1016\/j.vaccine.2018.09.041","article-title":"Tetanus-diphtheria vaccination in adults: the long-term persistence of antibodies is not dependent on polyclonal B-cell activation and the defective response to diphtheria toxoid re-vaccination is associated to HLADRB1 *01","volume":"36","author":"Ferlito","year":"2018","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100556_b0165","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.vaccine.2016.11.017","article-title":"Polio vaccines: WHO position paper, March 2016-recommendations","volume":"35","year":"2017","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100556_b0170","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2014.19.7.20705","article-title":"Immunity against poliomyelitis in the Netherlands, assessed in 2006 to 2007: the importance of completing a vaccination series","volume":"19","author":"van der Maas","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jvacx.2024.100556_b0175","article-title":"Expert review on poliovirus immunity and transmission","author":"Duintjer Tebbens","year":"2012","journal-title":"Risk Anal"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100556_b0180","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1086\/427810","article-title":"Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion","volume":"191","author":"Abbink","year":"2005","journal-title":"J Infect Dis"},{"issue":"7537","key":"10.1016\/j.jvacx.2024.100556_b0185","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/bmj.38719.435833.7C","article-title":"Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis","volume":"332","author":"Lee","year":"2006","journal-title":"BMJ"},{"issue":"27","key":"10.1016\/j.jvacx.2024.100556_b0190","article-title":"Hepatitis B vaccines: WHO position paper \u2013 July 2017","volume":"92","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"issue":"Suppl_4","key":"10.1016\/j.jvacx.2024.100556_b0195","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1093\/infdis\/jiaa668","article-title":"Hepatitis B vaccines","volume":"224","author":"Pattyn","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jvacx.2024.100556_b0200","unstructured":"Vaccine Scheduler [Internet]. [cited 1-9-2021]. Available from: https:\/\/vaccine-schedule.ecdc.europa.eu\/."},{"issue":"7","key":"10.1016\/j.jvacx.2024.100556_b0205","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapediatrics.2017.0638","article-title":"The influence of maternally derived antibody and infant age at vaccination on infant vaccine responses: an individual participant meta-analysis","volume":"171","author":"Voysey","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100556_b0210","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1086\/315870","article-title":"Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration","volume":"182","author":"Fernandez","year":"2000","journal-title":"J Infect Dis"},{"issue":"39","key":"10.1016\/j.jvacx.2024.100556_b0215","first-page":"413","article-title":"Haemophilus influenzae type b (Hib) Vaccination Position Paper - July 2013","volume":"88","year":"2013","journal-title":"Wkly Epidemiol Rec"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100556_b0220","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jama.2013.228052","article-title":"Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial","volume":"310","author":"Spijkerman","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100556_b0225","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.vaccine.2020.11.018","article-title":"Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands","volume":"39","author":"Peckeu","year":"2021","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100556_b0230","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/S1473-3099(20)30492-8","article-title":"Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UK","volume":"21","author":"Ladhani","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100556_b0235","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(23)00706-5","article-title":"Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study","volume":"24","author":"Bertran","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100556_b0240","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1183\/13993003.01451-2015","article-title":"Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden","volume":"47","author":"Galanis","year":"2016","journal-title":"Eur Respir J"},{"issue":"52","key":"10.1016\/j.jvacx.2024.100556_b0245","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1016\/j.vaccine.2013.10.032","article-title":"Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway","volume":"31","author":"Steens","year":"2013","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100556_b0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194823","article-title":"Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands","volume":"13","author":"Vissers","year":"2018","journal-title":"PLoS One"},{"issue":"29","key":"10.1016\/j.jvacx.2024.100556_b0255","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1016\/j.vaccine.2022.05.011","article-title":"Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study","volume":"40","author":"Savulescu","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100556_b0260","article-title":"Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study","author":"Ohm","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jvacx.2024.100556_b0265","article-title":"Effectiveness of meningococcal vaccines at reducing invasive meningococcal disease and pharyngeal Neisseria meningitidis carriage: a systematic review and meta-analysis","author":"McMillan","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100556_b0270","doi-asserted-by":"crossref","first-page":"e582","DOI":"10.1016\/S2589-7500(23)00108-5","article-title":"Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium","volume":"5","author":"Shaw","year":"2023","journal-title":"Lancet Digit Health"},{"issue":"34","key":"10.1016\/j.jvacx.2024.100556_b0275","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1016\/j.vaccine.2023.06.078","article-title":"Surveillance of Neisseria meningitidis carriage four years after menACWY vaccine implementation in the Netherlands reveals decline in vaccine-type and rise in genogroup e circulation","volume":"41","author":"Miellet","year":"2023","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100556_b0280","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1473-3099(20)30842-2","article-title":"Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey results","volume":"21","author":"MacLennan","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"36","key":"10.1016\/j.jvacx.2024.100556_b0285","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1016\/j.vaccine.2017.06.007","article-title":"Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: optimal age for vaccination","volume":"35","author":"van Ravenhorst","year":"2017","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.jvacx.2024.100556_b0290","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1001\/jama.2020.20449","article-title":"Association of use of a meningococcus group B vaccine with group B invasive meningococcal disease among children in Portugal","volume":"324","author":"Rodrigues","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jvacx.2024.100556_b0295","unstructured":"National Institute for Public Health and the Environment (RIVM). Meningococcal disease serogroup B: updated information for the Dutch Health Council; 2022."},{"issue":"1","key":"10.1016\/j.jvacx.2024.100556_b0300","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-021-06702-7","article-title":"Outbreaks of mumps genotype G viruses in the Netherlands between October 2019 and March 2020: clusters associated with multiple introductions","volume":"21","author":"Shah","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100556_b0305","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.jaci.2017.11.047","article-title":"Mumps infection but not childhood vaccination induces persistent polyfunctional CD8(+) T-cell memory","volume":"141","author":"de Wit","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"16","key":"10.1016\/j.jvacx.2024.100556_b0310","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.vaccine.2016.02.070","article-title":"Severity of mumps disease is related to MMR vaccination status and viral shedding","volume":"34","author":"Gouma","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100556_b0315","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiz188","article-title":"A third dose of measles-mumps-rubella vaccine to improve immunity against mumps in young adults","author":"Kaaijk","year":"2019","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100556_b0320","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/infdis\/jiz159","article-title":"Early measles vaccination during an outbreak in the Netherlands: short-term and long-term decreases in antibody responses among children vaccinated before 12 months of age","volume":"220","author":"Brinkman","year":"2019","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.jvacx.2024.100556_b0325","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/infdis\/jiw586","article-title":"Effectiveness of early measles, mumps, and rubella vaccination among 6\u201314-month-old infants during an epidemic in the Netherlands: an observational cohort study","volume":"215","author":"Woudenberg","year":"2017","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100556_b0330","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.vaccine.2019.10.090","article-title":"The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness - a systematic review","volume":"38","author":"Hughes","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100556_b0335","unstructured":"LCI Richtlijn Rodehond, bijlage Rubellascreeningsbeleid bij zwangere vrouwen; 2017. Available from: https:\/\/lci.rivm.nl\/richtlijnen\/rodehond."},{"issue":"9","key":"10.1016\/j.jvacx.2024.100556_b0340","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1017\/S0950268808001982","article-title":"Feasibility of a rubella screening and vaccination programme for unvaccinated young women","volume":"137","author":"Ruijs","year":"2009","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jvacx.2024.100556_b0345","doi-asserted-by":"crossref","DOI":"10.1093\/eurpub\/ckx017","article-title":"Increase in vaccination coverage between subsequent generations of orthodox Protestants in The Netherlands","author":"Spaan","year":"2017","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.jvacx.2024.100556_b0350","unstructured":"Netherlands Comprehensive Cancer Organisation (IKNL). NKR data; 2021. Available from: iknl.nl\/nkr-cijfers."},{"issue":"2","key":"10.1016\/j.jvacx.2024.100556_b0355","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ijc.31315","article-title":"Epidemiologic associations of HPV-positive oropharyngeal cancer and (pre)cancerous cervical lesions","volume":"143","author":"Rietbergen","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jvacx.2024.100556_b0360","unstructured":"World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020."},{"key":"10.1016\/j.jvacx.2024.100556_b0365","unstructured":"Gezondheidsraad. Aanpassing doses HPV-vaccinatie; 2022. Contract No.: 2022\/20."},{"issue":"10","key":"10.1016\/j.jvacx.2024.100556_b0370","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1002\/ijc.31231","article-title":"Vaccination protects against invasive HPV-associated cancers","volume":"142","author":"Luostarinen","year":"2018","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100556_b0375","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/cid\/ciz239","article-title":"Dose-related effectiveness of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia: a Danish nationwide cohort study","volume":"70","author":"Verdoodt","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100556_b0380","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.vaccine.2019.12.017","article-title":"Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: a systematic review of evidence from clinical trials","volume":"38","author":"Whitworth","year":"2020","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100556_b0385","article-title":"Immunogenicity of alternative dosing schedules for HPV vaccines among adolescent girls and young women: a systematic review and meta-analysis","volume":"8","author":"Secor","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100556_b0390","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.vaccine.2014.09.023","article-title":"Comparison of NITAG policies and working processes in selected developed countries","volume":"33","author":"Ricciardi","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100556_b0395","unstructured":"State secretary of Health WaS. Letter to the house of representatives on Vaccine coverage annual report 2022 and progress in approach \u201cconfidence in vaccinations\u201d [in Dutch]; 2023. Available from: https:\/\/open.overheid.nl\/documenten\/354c19a3-54ed-4c09-a125-585371b45138\/file."},{"issue":"3","key":"10.1016\/j.jvacx.2024.100556_b0400","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/eurpub\/ckq172","article-title":"Information on vaccination: meeting the needs of unvaccinated youngsters in the Netherlands","volume":"21","author":"Ruijs","year":"2011","journal-title":"Eur J Public Health"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100556_b0405","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-018-5103-8","article-title":"Under-vaccinated groups in Europe and their beliefs, attitudes and reasons for non-vaccination; two systematic reviews","volume":"18","author":"Fournet","year":"2018","journal-title":"BMC Public Health"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224001293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224001293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T19:45:29Z","timestamp":1732823129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136224001293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":81,"alternative-id":["S2590136224001293"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100556","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A literature review and evidence-based evaluation of the Dutch national immunisation schedule yield possibilities for improvements","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100556","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100556"}}